Health
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomized, double-blind, controlled, phase 3 trial – MD Linx
MDLinx original journal summary on Vaccines, Internal Medicine from The Lancet
Findings demonstrate the high efficacy of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG), in preventing laboratory-confirmed symptomatic COVID-19 disease in adults….
Continue Reading
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News16 hours agoGood character references restricted in rape cases in Queensland
-
General13 hours agoDairy farmers devastated by floods across parts of New South Wales